The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|June 19, 2017
PAREXEL Introduces its Connected Journey
Advertisement
BOSTON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation, a global biopharmaceutical services provider, announced the launch of its Connected Journey™ of data-driven services. This new network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology and processes, to deliver critical intelligence supporting clinical development and commercialization.
PAREXEL’s Connected Journey consists of over 40 data-driven services. Its most recent, the ForeSite™ clinical trial methodology, integrates therapeutic area expertise, real-time analytics technology, and centralized oversight to predict site productivity. The solution enables sponsors to improve feasibility and site and country selection, as well as to more effectively engage and retain sites and patients.
“While drug companies have access to more data sources than ever before, they face challenges in generating and integrating meaningful insights that drive timely and actionable decisions,” said Mark A. Goldberg, MD, president and COO, PAREXEL. “Aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development and commercialization spectrum. We believe PAREXEL’s global scale and broad technical expertise offer clients a uniquely integrated and comprehensive portfolio-delivered by a single provider.”
“The data resources to inform decision making are available, but to yield true value they must all be brought together,” said Xavier Flinois, president, PAREXEL Informatics. “PAREXEL’s Connected Journey moves from single solutions to the industry’s largest system of interrelated data-driven innovations. This model seamlessly connects data, technology, processes and multi-functional expertise, and is designed to foster close collaboration with all constituents.”
Contacts:
Media:
Dana Robie
Tel.: +1 781-434-4772
Email:
Kathryn McMahon, PAN Communications
Tel: +1 617-502-4300
Email:
Investors:
Ronald Aldridge
Tel.: +1-781-434-4753
Email:
Advertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5